Influence of Angiotensin II receptors blocking on overall left ventricle’s performance of patients with acute myocardial infarction of limited extent. Echocardiographic assessment
- 46 Downloads
Recent studies documented the beneficial effect of angiotensin-receptor blockers (ARBs) on patients (pts) with acute myocardial infarction (AMI) combined with left ventricle (LV) systolic dysfunction. The present study intended to assess the impact of the ARB irbesartan, on the overall LV performance in pts with uncomplicated AMI of limited extent.
Forty consecutive pts with first inferior AMI (AMI-I) and preserved LV-systolic function were enrolled. They were allocated into two groups: (a) 20 pts received the conventional treatment of AMI-I and placebo (CT) and (b) 20 pts administered irbesartan additionally to the conventional treatment (IR). Twenty four healthy individuals of matching age and sex were recruited as control group (CG). Complete echocardiographic examination, Tei index of overall LV function and systolic blood pressure (SBP) were measured on the 8th post-infarct day.
The Tei index of IR group (0.53±0.03) was significantly lower compared to that of CT group (0.78±0.05) (p<0.001) and was similar to that of CG (0.45±0.03)(p=NS). Irbesartan induced a considerable decrease in both isovolumic relaxation (115±7 ms vs 140±7 ms; p<0.01) and contraction time (52±2 ms vs 64±3 ms; p<0.01) and a significant increase in ejection time (279±6 ms vs 256±8 ms; p<0.05). SBP in pts of IR group was similar to that of CT group (112±3 mmHg vs 113±4 mmHg; p=NS).
Therapy with Irbesartan improves overall LV function of pts with AMI-I. Irbesartan leads to acceleration of the LV relaxation, which possibly indirectly ameliorates LV systolic performance too. This beneficial influence is possible attributed to a direct tissue effect of the drug and not to its hemodynamic action.
KeywordsAcute myocardial infarction of limited extent Irbesartan Tei index
Unable to display preview. Download preview PDF.
- 4.The Acute Infarction Ramipril Efficacy (AIRE) (1993). Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–8Google Scholar
- 5.Grouppo Italiano per Io Studio della Streptochinasi nell’ Infarcto Miocardico. (1994). GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 343:1115–21Google Scholar
- 7.Petrie M, Padmanabhan N, McDonald J, Hillier C, Connell J, McMurray J. (2001). Angiotensin converting enzyme (ACE) and non ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37:1056–61CrossRefPubMedGoogle Scholar
- 11.Pitt B, Poole-Wilson P, Segal R, et al. (1999). Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study- ELITE II. J Card Fail 5:146–54CrossRefPubMedGoogle Scholar
- 12.Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. (2001). Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–8CrossRefPubMedGoogle Scholar
- 28.Moller J, Dahlstrom U, Gotzsche O et al. (2004). Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: Results of the Optimal trial in myocardial infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 147:494–501CrossRefPubMedGoogle Scholar